Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The 2016 Assisi Think Tank Meeting on breast cancer: white paper.
Aristei C, Kaidar-Person O, Arenas M, Coles C, Offersen BV, Bourgier C, Frezza G, Leonardi MC, Valentini V, Poortmans PM. Aristei C, et al. Among authors: offersen bv. Breast Cancer Res Treat. 2016 Nov;160(2):211-221. doi: 10.1007/s10549-016-3998-2. Epub 2016 Sep 29. Breast Cancer Res Treat. 2016. PMID: 27686462
The Nordic Cardio-Oncology Society: mission and future goals.
Gulati G, Broberg AM, Offersen BV. Gulati G, et al. Among authors: offersen bv. Eur Heart J. 2024 Jun 1;45(21):1869-1871. doi: 10.1093/eurheartj/ehae014. Eur Heart J. 2024. PMID: 38607440 No abstract available.
Quality assurance of conventional non-CT-based internal mammary lymph node irradiation in a prospective Danish Breast Cancer Cooperative Group trial: the DBCG-IMN study.
Thorsen LB, Thomsen MS, Overgaard M, Overgaard J, Offersen BV; Danish Breast Cancer Cooperative Group Radiotherapy Committee. Thorsen LB, et al. Among authors: offersen bv. Acta Oncol. 2013 Oct;52(7):1526-34. doi: 10.3109/0284186X.2013.813643. Epub 2013 Aug 19. Acta Oncol. 2013. PMID: 23957621
Radiotherapy for breast cancer, the TARGIT-A trial.
Yarnold J, Offersen BV, Olivotto I, Poortmans P, Sarin R. Yarnold J, et al. Among authors: offersen bv. Lancet. 2014 May 17;383(9930):1717-8. doi: 10.1016/S0140-6736(14)60828-X. Lancet. 2014. PMID: 24835611 No abstract available.
Haste makes waste: are the data regarding TARGIT-A IORT ready for prime time?
Kaidar-Person O, Poortmans P, Klimberg S, Haviland J, Offersen B, Audisio R, Yarnold J. Kaidar-Person O, et al. Breast Cancer Res Treat. 2014 Aug;147(1):221-2. doi: 10.1007/s10549-014-3032-5. Epub 2014 Jul 22. Breast Cancer Res Treat. 2014. PMID: 25048466 No abstract available.
ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer.
Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopek N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P. Offersen BV, et al. Radiother Oncol. 2015 Jan;114(1):3-10. doi: 10.1016/j.radonc.2014.11.030. Epub 2015 Jan 24. Radiother Oncol. 2015. PMID: 25630428
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Gourgou-Bourgade S, et al. Among authors: offersen bv. Ann Oncol. 2015 May;26(5):873-879. doi: 10.1093/annonc/mdv106. Epub 2015 Feb 27. Ann Oncol. 2015. PMID: 25725046 Free article. Review.
155 results